SYCUMEBeyond's analysis on SYCUME2026-10-09 — Innovent's phase 3 trial shows SYCUME reduces eye protrusion in inactive thyroid eye disease, positioning the drug for potential approvalRecent news mentioning SYCUME2026-10-09 — Innovent Announces Phase 3 RESTORE-3 Study of SYCUME® (Teprotumumab N01 Injection) Met Primary Endpoint in Inactive Thyroid Eye DiseaseAppears alongsideN01Browse the full archive →